Imperial College London
Portrait Picture

ProfessorJamesWare

Faculty of Medicine, National Heart & Lung Institute

Professor of Cardiovascular and Genomic Medicine
 
 
 
//

Contact

 

j.ware Website

 
 
//

Assistant

 

Ms Lisa Quinn +44 (0)20 7594 1345

 
//

Location

 

3 13GLMS BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Minikel:2020:10.1038/s41586-020-2267-z,
author = {Minikel, EV and Karczewski, KJ and Martin, HC and Cummings, BB and Whiffin, N and Rhodes, D and Alföldi, J and Trembath, RC and van, Heel DA and Daly, MJ and Genome, Aggregation Database Production Team and Genome, Aggregation Database Consortium and Schreiber, SL and MacArthur, DG},
doi = {10.1038/s41586-020-2267-z},
journal = {Nature},
pages = {459--464},
title = {Evaluating potential drug targets through human loss-of-function genetic variation},
url = {http://dx.doi.org/10.1038/s41586-020-2267-z},
volume = {581},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Naturally occurring human genetic variants predicted to inactivate protein-coding genes provide an in vivo model of human gene inactivation that complements cell and model organism knockout studies. Here we report three key findings regarding assessment of candidate drug targets using human loss-of-function variants. First, even essential genes, where loss-of-function variants are not tolerated, can be highly successful as targets of inhibitory drugs. Second, in most genes, loss-of-function variants are sufficiently rare that genotype-based ascertainment of homozygous or compound heterozygous “knockout” humans will await sample sizes ~1,000 times those presently available, unless recruitment focuses on consanguineous individuals. Third, automated variant annotation and filtering are powerful, but manual curation remains critical for removing artifacts, and is a prerequisite for recall-by-genotype efforts. Our results provide a roadmap for human “knockout” studies and should guide interpretation of loss-of-function variants in drug development.
AU  - Minikel,EV
AU  - Karczewski,KJ
AU  - Martin,HC
AU  - Cummings,BB
AU  - Whiffin,N
AU  - Rhodes,D
AU  - Alföldi,J
AU  - Trembath,RC
AU  - van,Heel DA
AU  - Daly,MJ
AU  - Genome,Aggregation Database Production Team
AU  - Genome,Aggregation Database Consortium
AU  - Schreiber,SL
AU  - MacArthur,DG
DO  - 10.1038/s41586-020-2267-z
EP  - 464
PY  - 2020///
SN  - 0028-0836
SP  - 459
TI  - Evaluating potential drug targets through human loss-of-function genetic variation
T2  - Nature
UR  - http://dx.doi.org/10.1038/s41586-020-2267-z
UR  - http://hdl.handle.net/10044/1/78192
VL  - 581
ER  -
Download